Kallikrein 9 antibody (C-Term)

Catalog No. ABIN3043038

This anti-Kallikrein 9 antibody is a Rabbit Polyclonal antibody detecting Kallikrein 9 in WB. Suitable for Human.

Quick Overview for Kallikrein 9 antibody (C-Term) (ABIN3043038)

Target: Kallikrein 9 (KLK9)

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This Kallikrein 9 antibody is un-conjugated

Application: Western Blotting (WB)

Product Details anti-Kallikrein 9 Antibody

Binding Specificity: AA 236-250, C-Term

Purpose: Anti-Kallikrein 9/KLK9 Antibody Picoband®

Sequence: SVCHYLDWIQ EIMEN

Cross-Reactivity (Details): No cross-reactivity with other proteins

Characteristics: Anti-Kallikrein 9/KLK9 Antibody (ABIN3043038). Tested in WB applications. This antibody reacts with Human. The brand Picoband indicates this is a premium antibody that guarantees superior quality, high affinity, and strong signals with minimal background in Western blot applications. Only our best-performing antibodies are designated as Picoband, ensuring unmatched performance.

Purification: Immunogen affinity purified.

Immunogen: A synthetic peptide corresponding to a sequence at the C-terminus of human Kallikrein 9.

Isotype: IgG

Application Details

Application Notes: Western blot, 0.1-0.5 μg/mL, Human
1. Yousef, G. M., Diamandis, E. P. The expanded human kallikrein gene family: locus characterization and molecular cloning of a new member, KLK-L3 (KLK9). Genomics 65: 184-194, 2000. 2. Yousef, G. M., Kyriakopoulou, L. G., Scorilas, A., Fracchioli, S., Ghiringhello, B., Zarghooni, M., Chang, A., Diamandis, M., Giardina, G., Hartwick, W. J., Richiardi, G., Massobrio, M., Diamandis, E. P., Katsaros, D. Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker. Cancer Res. 61: 7811-7818, 2001.

Comment:

Antibody can be supported by chemiluminescence kit ABIN921124 in WB.

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Add 0.2 mL of distilled water will yield a concentration of 500 μg/mL.

Concentration: 500 μg/mL

Buffer: Each vial contains 5 mg BSA, 0.9 mg NaCl, 0.2 mg Na2HPO4, 0.05 mg Thimerosal, 0.05 mg Sodium azide.

Preservative: Thimerosal (Merthiolate), Sodium azide

Precaution of Use: This product contains Thimerosal (Merthiolate) and Sodium azide: POISONOUS AND HAZARDOUS SUBSTANCES which should be handled by trained staff only.

Handling Advice: Avoid repeated freezing and thawing.

Storage: 4 °C,-20 °C

Storage Comment: Store at -20°C for one year from date of receipt. After reconstitution, at 4°C for one month.
It can also be aliquotted and stored frozen at -20°C for six months. Avoid repeated freeze-thaw cycles.

Expiry Date: 12 months

Target Details for Kallikrein 9

Target: Kallikrein 9 (KLK9)

Alternative Name: KLK9

Background:

Synonyms: Kallikrein-9;3.4.21.-;Kallikrein-like protein 3;KLK-L3;KLK9;

Tissue Specificity: Skin, thymus, trachea, cerebellum and spinal cord.

Background: KLK9 (kallikrein-related peptidase 9) also known as kallikrein 9 or KLK-L3, belongs to the kallikrein subgroup of serine proteases, which have diverse physiologic functions in many tissues. The KLK9 gene contains 5 coding exons and is mapped to 19q13.41. The KLK9 gene is regulated by steroid hormones in a human breast cancer cell line. Yousef et al. (2001) performed a quantitative analysis of KLK9 expression in ovarian cancer. The results indicated thatKLK9 is under steroid hormone regulation in ovarian and breast cancer cell lines. KLK9 is a potential independent favorable prognostic marker for early-stage, low-grade, optimally debulked ovarian cancer patients.

Sequence Similarities: Belongs to the peptidase S1 family. Kallikrein subfamily.

Molecular Weight: 35 kDa

Pathways: Complement System